Dov Goldstein, MD
Board Member – Director
Dr. Dov Goldstein joined the Board of Directors of Topaz Pharmaceuticals in December 2007. Dr. Goldstein
currently serves as a Partner of Aisling Capital. Previously, Dr. Goldstein was Executive Vice President and
Chief Financial Officer of Vicuron Pharmaceuticals (now Pfizer). While at Vicuron, he led the valuation and
finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI). Prior to Vicuron, Dr. Goldstein
was Director of Venture Analysis at HealthCare Ventures. Dr. Goldstein received his MD from Yale
School of Medicine. He received his MBA from Columbia Business School and his BS (with honors) from Stanford
University.
|
|
